Merck & Co, AstraZeneca and Alexion are all in line for exits after Moderna Therapeutics, valued at $7.5bn earlier this year, filed for its initial public offering.

US-based vaccine developer Moderna Therapeutics has filed to raise up to $500m in an initial public offering that would enable pharmaceutical firms Merck & Co, AstraZeneca and Alexion Pharmaceuticals to exit. Founded in 2010, Moderna is working on vaccines and drugs based on messenger RNA and it has a pipeline of 21 product candidates with…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.